Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity
暂无分享,去创建一个
Scott E. Martin | Eugen C. Buehler | M. A. Resnick | D. Menendez | M. Lal-Nag | Scott E Martin | J. Nitiss | Jay R. Anand | Jiaqi Fu | Carri C. Murphy | Whitney J. Bell | Nadia Slepushkina | C. C. Murphy | Jay Anand | M. Resnick | Carri Murphy
[1] N. Osheroff,et al. Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors. , 2021, Biochemistry.
[2] Y. Pommier,et al. A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation , 2020, Science Advances.
[3] J. Berger,et al. Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast , 2020, Proceedings of the National Academy of Sciences.
[4] Y. Pommier,et al. Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). , 2020, DNA repair.
[5] Y. Pommier,et al. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity , 2020, eLife.
[6] Kejiao Li,et al. A Genetic Map of the Response to DNA Damage in Human Cells , 2019, Cell.
[7] J. Bargonetti,et al. Gain-of-function mutant p53: history and speculation , 2019, Journal of molecular cell biology.
[8] R. London,et al. ZATT (ZNF451)–mediated resolution of topoisomerase 2 DNA-protein cross-links , 2017, Science.
[9] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[10] D. Menendez,et al. The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53 , 2017, Molecular Cancer Research.
[11] Y. Pommier,et al. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability , 2016, Nature Reviews Molecular Cell Biology.
[12] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[13] M. DePamphilis,et al. Identification of genes that are essential to restrict genome duplication to once per cell division , 2016, Oncotarget.
[14] G. Jackson,et al. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II , 2016, Biochemical pharmacology.
[15] Reham Atteya,et al. Topoisomerase-mediated chromosomal break repair: an emerging player in many games , 2015, Nature Reviews Cancer.
[16] Davide Heller,et al. STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..
[17] R. Muschel,et al. Targeting ATR in DNA damage response and cancer therapeutics. , 2014, Cancer treatment reviews.
[18] Johannes M. Freudenberg,et al. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells , 2013, Nucleic acids research.
[19] X. Jacq,et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. , 2013, Journal of medicinal chemistry.
[20] I. Kubacka,et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. , 2012, Genes & development.
[21] Oscar Fernandez-Capetillo,et al. Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs , 2011, Molecular oncology.
[22] E. Brown,et al. Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and p53 , 2009, Nature Genetics.
[23] Y. Pommier. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. , 2009, Chemical reviews.
[24] J. Nitiss. DNA topoisomerase II and its growing repertoire of biological functions , 2009, Nature Reviews Cancer.
[25] J. Nitiss. Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.
[26] D. Cortez,et al. ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.
[27] M. Klagsbrun,et al. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine , 2008, British Journal of Cancer.
[28] Jesse D. Martinez,et al. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.
[29] Marc Ferrer,et al. Median Absolute Deviation to Improve Hit Selection for Genome-Scale RNAi Screens , 2008, Journal of biomolecular screening.
[30] H. Koyama,et al. Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM. , 2007, DNA and cell biology.
[31] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[32] F. Bunz,et al. Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival , 2007, Molecular Cancer Therapeutics.
[33] C. Chiu,et al. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis , 2005, Apoptosis.
[34] A. Sartorelli,et al. Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(–/–) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors* , 2004, Journal of Biological Chemistry.
[35] G. Stark,et al. G2 arrest in response to topoisomerase II inhibitors: the role of p53. , 2003, Cancer research.
[36] D. Sullivan,et al. Tumor p53 status and response to topoisomerase II inhibitors. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[37] B. Kaina,et al. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. , 2003, DNA repair.
[38] R. Paules,et al. ATR Enforces the Topoisomerase II-dependent G2 Checkpoint through Inhibition of Plk1 Kinase* , 2002, The Journal of Biological Chemistry.
[39] S. Schreiber,et al. ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint* , 2002, The Journal of Biological Chemistry.
[40] J. Darbon,et al. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. , 2001, Biochemical and biophysical research communications.
[41] N. Pellegata,et al. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions. , 2001, Anticancer research.
[42] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[43] S. Inoue,et al. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase. , 1998, Carcinogenesis.
[44] G. Zambetti,et al. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor , 1997, Molecular and cellular biology.
[45] T. Jacks,et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.
[46] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[47] M. Fritsche,et al. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.
[48] J. Wang,et al. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[49] Yilun Sun,et al. Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells. , 2018, Methods in molecular biology.
[50] D. J. Clarke,et al. DNA Topoisomerases , 2009, Methods in Molecular Biology™.
[51] C. Harris,et al. p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.
[52] M. Boiocchi,et al. Pharmacokinetic Optimisation of Treatment with Oral Etoposide , 2004, Clinical pharmacokinetics.
[53] D. Banerjee,et al. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines. , 1999, Journal of cellular biochemistry.
[54] Mark T. Muller,et al. Dna Repair : Possible Relationship with in Vivo I-dna Complex Formation Ultraviolet-induced Dna Damage Stimulates Topoisomerase Updated Version Citing Articles E-mail Alerts Ultraviolet-induced Dna Damage Stimulates Topoisomerase I-dna Complex Formation in Vivo: Possible Relationship with Dna Repair , 2022 .